Solowin Holdings (NASDAQ: AXG) reported preliminary, unaudited results for the fiscal year ended March 31, 2026, highlighting revenue growth to between $27 million and $29 million, nearly ten times higher year over year, driven by expansion in digital asset tokenization, stablecoin infrastructure, and AI-powered services. The company reported a net loss of $11 million to $13 million amid…
Beeline Holdings (NASDAQ: BLNE) will host a stakeholder update call on its first-quarter 2026 results on Thursday, May 14, 2026, at 5 p.m. ET. The call will be led by Chief Executive Officer Nick Liuzza and Chief Financial Officer Chris Moe, who are expected to review the company’s performance and provide updates on ongoing initiatives. To view the full…
Dr. Christopher J. Schaber outlines strategies for navigating constrained funding environment Soligenix (NASDAQ: SNGX) CEO Dr. Christopher J. Schaber emphasized the importance of capital discipline in a Pharmaphorum analysis examining how biotech companies can succeed in today’s constrained funding environment, where even late-stage programs may struggle to secure investment. The article notes that strong science alone is no longer sufficient,…
Channelchek, a Noble Financial Group platform, highlights a changing investment landscape in 2025, where capital is increasingly rotating toward differentiated growth opportunities beyond crowded sectors. Within this environment, Enhanced Group Inc.—an emerging sports, media, and consumer health company—is pursuing a public market debut through a proposed business combination with A Paradise Acquisition Corp. (NASDAQ: APAD), positioning itself within…
NRx Pharmaceuticals (NASDAQ: NRXP) welcomed a newly signed Executive Order aimed at accelerating medical treatments for serious mental illness, including expanded access to psychedelic therapies and faster regulatory pathways. The order directs the FDA to issue priority vouchers for qualifying breakthrough therapies and encourages broader use of clinical trial data and real-world evidence, aligning with NRx’s…
This article has been disseminated on behalf of Planet Ventures Inc. and may include paid advertising. Planet Ventures (CSE: PXI) (OTC Pink: PNXPF) (FSE: P6U) announced it has adopted a Disclosure, Confidentiality and Insider Trading Policy to strengthen compliance with Canadian securities laws, prevent selective disclosure and ensure proper handling of material information, while also updating its Investment Policy to…
By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader Soligenix (NASDAQ: SNGX) is emphasizing the strategic importance of patient-centric drug development, as outlined by CEO Christopher J. Schaber in a Clinical Leader guest column, which explores how reformulating therapies can improve access, adherence, and real-world viability. Drawing on the company’s experience with SGX945, Schaber explains that…
Safe Pro Group (NASDAQ: SPAI) reported continued execution of its share repurchase program, with 400,000 shares repurchased as of April 17, 2026, representing approximately 3.5% of its public float under a $3.0 million authorization approved in December 2025. The company funded repurchases through operating cash flow and its strong balance sheet, which included $16.7 million in cash and no…
Amid increased demand for advanced collision-avoidance systems as rail networks grow more complex, Rail Vision’s (NASDAQ: RVSN) artificial-intelligence (“AI”)-powered electro-optical sensors are emerging as a direct technological response. “Rail Vision develops vision-based detection systems designed to improve railway safety and operational performance, offering real-time obstacle detection and situational awareness that align closely with evolving safety priorities across the…
Boca Raton, Florida-based LIXTE Biotechnology Holdings (NASDAQ: LIXT) spent 2025 expanding its presence across multiple segments of oncology innovation. “The company is best known for its clinical-stage pharmaceutical pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (‘PP2A’),” a recent article reads. “Rather than replacing established cancer therapies, LB-100 is designed to enhance their effectiveness.…
Artificial intelligence-powered cardiovascular medicine company Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its focus on cardiovascular disease prevention, detection, and management. The publication reads, “The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators… At the core of…
HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses, with the transaction completed on April 16, 2026. The offering, supported by key stakeholders including ClearCardio(TM), company leadership and institutional investors, will fund commercialization of HeartBeam’s FDA-cleared 12-lead synthesized…
Datavault AI (NASDAQ: DVLT) a provider of data monetization, credentialing, digital engagement and real-world asset tokenization technologies, announced that the first sites of its quantum-ready high-performance computing GPU network are now live in New York and Philadelphia, with full commercial availability of its planned 48,000-GPU fleet expected in Q3 2026. The network, designed to operate outside the hyperscaler supply chain, will…
Safe Pro Group (NASDAQ: SPAI), an AI-enabled defense and security solutions provider, announced it successfully completed a U.S. Army live fire exercise where its patented AI technology processed drone imagery at the edge to detect live scattered mines and deliver actionable intelligence to commanders. The exercise builds on a prior government contract and supports the rollout…
Polyrizon (NASDAQ: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, announced the closing of its previously announced registered direct offering and concurrent private placement with a single institutional investor, generating approximately $3.5 million in gross proceeds. The transactions included the sale of 388,888 units or pre-funded units at a combined price of $9.00 per unit, consisting…
Massimo Group (NASDAQ: MAMO) announced it has entered into a strategic cooperation agreement with Shenzhen AIBO Robotics Co. Ltd. to support expansion into intelligent commercial automation, robotic service systems and AI-enabled equipment upgrades, initially targeting the United States and China. The company plans to leverage its manufacturing, deployment and commercialization capabilities to scale robotics solutions across…
NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression and PTSD, announced the formation of NRx Defense Systems Inc., a Florida-based research and development subsidiary dedicated to advancing combined neuroplastic treatments using D-cycloserine and transcranial magnetic stimulation supported by robotic-enabled neuronavigation. The subsidiary will be led by Dr. Dennis McBride, with…
HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it is commencing an underwritten public offering of shares of its common stock or common stock equivalents, with all securities to be offered by the company and the final size and terms subject to market conditions. The company said it intends to…
Beeline Holdings (NASDAQ: BLNE) announced a strategic partnership with Structured Real Estate Group to integrate its Embedded Mortgage and Title solutions into SRG’s AI-driven real estate platform, enabling homebuyers to access personalized financing, evaluate total ownership costs and initiate the mortgage process within a single digital environment. The collaboration will support the development of approximately…
Soligenix (NASDAQ: SNGX) was featured in a recent article that discussed its positioning in a landscape where modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism can unlock treatments for multiple diseases. “Soligenix exemplifies this strategy through its use of synthetic hypericin across two distinct dermatologic indications, illustrating how platform science can streamline…